ClearGuard HD Caps Recommended for Preventing Bloodstream Infection

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

Pursuit Vascular, Inc. announced that the latest edition of NephSAP® featured the company’s ClearGuard HD Antimicrobial Barrier Caps as a key component of a global strategy to reduce bloodstream infections in hemodialysis patients. NephSAP, or Nephrology Self-Assessment Program, is a premiere educational offering for American Society of Nephrology (ASN) members to help them stay abreast of developing areas of nephrology.  The July edition highlights the significant reduction in central-line associated bloodstream infection (CLABSI) rates using ClearGuard HD caps vs. other commonly used caps.

Dr. Daniel Landry, Baystate Medical Center, notes the “dramatic and sustained reduction in CLABSI rates” using ClearGuard HD caps in the two “prospective multicenter randomized controlled trials encompassing more than 533,000 catheter-days” in his accompanying editorial.  He recommends “use of antimicrobial catheter caps for the purpose of preventing CLABSI” as a component of a global strategy to reduce bloodstream infections.

ClearGuard HD caps are also included as a specific prevention strategy for central venous catheters to reduce the risk of bloodstream infection by Eduardo Lacson, Jr., MD at Tufts University School of Medicine, and Alan Kliger, MD, of Yale School of Medicine.  They provide an overview of the two trials using ClearGuard HD caps and conclude “central venous catheter caps with chlorhexidine-coated rods decrease the risk of blood stream infections compared with standard caps or isopropanol-containing caps.”

The July edition of NephSAP is part of the Nephrologists Transforming Dialysis Safety (NTDS) project, an initiative funded by the Centers for Disease Control and Prevention (CDC) aimed at engaging nephrologists to promote infection prevention in dialysis facilities.

“It’s gratifying to see the CDC and ASN recognize ClearGuard HD caps in this special edition of NephSAP,” said Doug Killion, President and CEO of Pursuit Vascular.  “We share a common vision with NTDS in targeting zero infections, and ClearGuard HD caps help make this goal a reality.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles